A Phase 3 interventional study of Brexpiprazole and Antidepressant therapy in Major Depressive Disorder, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-10-12.
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies testing brexpiprazole in Depressive Disorder, Major — 1 open to participants now, 1 under way, none of them phase 3. brexpiprazole · Depressive Disorder, Major.
Among the 24 studies testing brexpiprazole in Depressive Disorder, Major, this one is the 4th largest by enrollment, is one of 4 that started in 2018, is one of 16 in phase 3, and was the 18th registered.
3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.
Browse Depressive Disorder, Major studies →1 of the 24 studies testing brexpiprazole in Depressive Disorder, Major is open now, in 1 country. Recruiting first, the newest first:
Nova Scotia Health Authority · Sites in Canada
Ages 18–65 · Healthy volunteers
By country, each count listing its studies:
brexpiprazole: first FDA approval 2015 (REXULTI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4 · Phase 3 17 · Phase 4 3
First in 2009; this study’s year is marked. 4 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,149 is above the median of 80 across 2,534 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 189 across the 24 interventional studies. Of the 21 that completed or were terminated, 19 (90%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 24 have an industry lead sponsor. The 6 most frequent:
This study is registered under Otsuka Pharmaceutical Development & Commercialization, Inc., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Otsuka Pharmaceutical Development & Commercialization, Inc. is the lead sponsor of 297 studies on the registry; 19 are open to participants now.
Of its 106 completed or terminated interventional studies of FDA-regulated products, 71 (67%) have results posted.
45 studies in Depressive Disorder, Major by Otsuka Holdings Co., Ltd.: none open now, none under way, none of them phase 3. Of 42 finished, 29 (69%) have results posted.
Among the 45 studies in Depressive Disorder, Major by Otsuka Holdings Co., Ltd., this one is the 6th largest by enrollment of the 40 interventional ones that give a count, is one of 5 that started in 2018, is one of 23 in phase 3, and was the 32nd registered.
Otsuka Holdings Co., Ltd.’s Depressive Disorder, Major studies by the year they started, since 2004.
None of the studies under way reaches primary completion within a year.
Among the 24 studies testing brexpiprazole in Depressive Disorder, Major, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Otsuka Holdings Co., Ltd.’s 45 in Depressive Disorder, Major:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Major depressive disorder (MDD) is a serious medical illness associated with significant suicidal risk and marked disability. Despite the availability of numerous treatments, achievement of consistent and favorable long-term outcomes remains challenging.
This study will assess the safety, efficacy and tolerability of brexpiprazole as adjunctive therapy to protocol-specific open-label antidepressant therapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants with a primary diagnosis of:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received brexpiprazole 2 or 3 milligrams per day (mg/day) along with protocol-specified antidepressant therapy (ADT), orally, for 6 to 8 weeks during Phase A. Participants were initially titrated to a target dose of brexpiprazole 2 mg over a 2 to 4-week period. Thereafter, participants who had not met response criteria as defined in the blinded addendum, did not have potentially dose-related adverse events (AEs), and had not achieved the maximum dose of medication had their dose increased up to 3 mg.
Drug: Brexpiprazole · Drug: Antidepressant therapy
Eligible participants completing Phase A were enrolled in Phase B to receive brexpiprazole 2 or 3 mg/day along with protocol-specified ADT, orally, for 12 weeks.
Drug: Brexpiprazole · Drug: Antidepressant therapy
Eligible participants completing Phase B received brexpiprazole 2 or 3 mg/day (dose of brexpiprazole that they were receiving at Week 20 of the Stabilization Phase) along with protocol-specified ADT, orally, for up to 26 weeks during Phase C.
Drug: Brexpiprazole · Drug: Antidepressant therapy
Eligible participants completing Phase B received brexpiprazole-matching placebo along with protocol-specified ADT, orally, for up to 26 weeks during Phase C.
Drug: Antidepressant therapy
Administered as tablets.
Also known as: OPC-34712, Rexulti
Protocol-specified oral ADTs included: citalopram hydrobromide (Celexa®) tablets, escitalopram (Lexapro®) tablets, fluoxetine (Prozac®) capsules, paroxetine (Paxil CR®) controlled-release tablets, sertraline (Zoloft®) tablets, duloxetine (Cymbalta®) delayed-release capsules, venlafaxine XR (Effexor XR®) extended-release (XR) capsules.
Phase C: Time-to-Relapse by Any Criteria as Defined in Blinded Addendum
Relapse criteria included:At same visit, increase in Montgomery Asberg Depression Rating Scale\[MADRS\] total score(10 items, 0=no symptoms to 6=severe symptoms,total score=0 to 60)of 50% from randomization and Clinical Global Impression-Severity of Illness \[CGI-\](8-point scale of 0=not assessed to 7=most extremely ill)score ≥4,hospitalization for depression, discontinuation for lack of efficacy/worsening of depression, active suicidality(score of ≥4 on MADRS item10 of suicidality)or yes answered on question 4 or 5 of Columbia-Suicide Severity Rating Scale\[C-SSRS\](Suicidal Ideation \[SI\] has 5 questions: wish to be dead,non-specific active suicidal thoughts,active SI with any methods \[not plan\]without intent to act,active SI with some intent to act without specific plan,active SI with specific plan,intent)or yes answered to any question in suicidal behavior section (5 questions:preparatory acts/behavior,aborted attempt,interrupted attempt,actual attempt\[non-fatal\],completed suicide).
Time frame: Up to 14 days post last dose in Phase C (up to 28 weeks)
Phase C: Change From Baseline for Randomization Phase in Sheehan Disability Scale (SDS) Mean Total Score at Week 46
The SDS is a self-rated instrument used to measure the effect of the participant's symptoms on work/school, social life, and family/home responsibilities. For each of the three items, scores range from 0 through 10. The number most representative of how much each area was disrupted by symptoms is marked along the line from 0=not at all, to 10=extremely. The SDS total score is the mean of the 3 item responses. The SDS total score ranges from 0 to 10, with higher scores indicating greater functional impairment. Baseline was defined as the last available assessment value between Week 14 and Week 20 in Phase B for this outcome measure. Analysis of covariance (ANCOVA) model was used for analysis.
Time frame: Baseline and Week 46
Phase C: Time-to-functional Relapse Based on SDS Criteria
Time-to-functional relapse was based on a 30% increase in the SDS mean total score from Phase C Baseline, at least one SDS sub-score at 4 or greater, and an SDS total score ≥7 when all 3 sub-scores were available. The SDS is a self-rated instrument used to measure the effect of the participant's symptoms on work/school, social life, and family/home responsibilities. For each of the three items, scores range from 0 through 10. The number most representative of how much each area was disrupted by symptoms is marked along the line from 0=not at all, to 10=extremely. Higher scores of 5 and above are associated with significant functional impairment.
Time frame: Up to 14 days post last dose in Phase C (up to 28 weeks)
Phase C: Percentage of Participants Meeting Any Relapse Criteria
Relapse criteria included: At the same visit, increase in MADRS total score (10 items,7-point scale of 0=no symptoms to 6=severe symptoms, total score of 0 to 60) of 50% from randomization and CGI-S (8-point scale ranging from 0=not assessed to 7=most extremely ill) score ≥4, hospitalization for depression, discontinuation for lack of efficacy/worsening of depression, active suicidality (score of ≥4 on MADRS item 10 of suicidality) or answer of yes on question 4 or 5 of C-SSRS (SI has 5 questions: wish to be dead, non-specific active suicidal thoughts, active SI with any methods \[not plan\] without intent to act, active SI with some intent to act without specific plan, active SI with specific plan, intent) or answer of yes to any question in suicidal behavior section (5 questions: preparatory acts/behavior, aborted attempt, interrupted attempt, actual attempt \[non-fatal\], completed suicide). Percentage of participants were rounded off to single decimal point.
Time frame: Up to 26 weeks in Phase C
Phase C: Percentage of Participants Maintaining Remission
Participants maintaining remission was defined as MADRS total score ≤10. The MADRS is a clinician-rated scale to assess depressive symptomatology during the preceding week. Participants were rated on 10 items (feelings of sadness, lassitude, pessimism, inner tension, suicidality, reduced sleep or appetite, difficulty concentrating, and a lack of interest) each on a 7-point scale from 0 (no symptoms) to 6 (symptoms of maximum severity). The total score ranges from 0 to 60 with a higher score indicating more depression.
Time frame: Weeks 21, 23, 25, 29, 33, 37, 41, 45, and 46
Phase C: Change From Baseline for Randomization Phase in MADRS Total Score at Week 46
The MADRS is a clinician-rated scale to assess depressive symptomatology during the preceding week. Participants were rated on 10 items (feelings of sadness, lassitude, pessimism, inner tension, suicidality, reduced sleep or appetite, difficulty concentrating, and a lack of interest) each on a 7-point scale from 0 (no symptoms) to 6 (symptoms of maximum severity). The total score ranges from 0 to 60 with a higher score indicating more depression. A positive change from Baseline indicates worsening of symptoms. Baseline was defined as the last available assessment value in Phase B for this outcome measure. ANCOVA model was used for analysis.
Time frame: Baseline and Week 46
Phase C: Change From Baseline for Randomization Phase in CGI-S Score at Week 46
The CGI -S was used to rate the severity of illness for each participant on an 8-point scale ranging from 0 to 7 where 0=not assessed, 1=normal, not at all ill, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severely ill, and 7=among the most extremely ill participants. A positive change from Baseline indicates worsening of illness. Baseline was defined as the last available assessment value in Phase B for this outcome measure. ANCOVA model was used for analysis.
Time frame: Baseline and Week 46
Phase C: Change From Baseline for Randomization Phase in Each of the SDS Individual Item Scores at Week 46
The SDS is a self-rated instrument used to measure the effect of the participant's symptoms on work/school, social life, and family/home responsibilities. For each of the three items, scores range from 0 through 10. The number most representative of how much each area was disrupted by symptoms is marked along the line from 0=not at all, to 10=extremely. Higher scores of 5 and above are associated with significant functional impairment. A positive change from Baseline indicates worsening of symptoms impacting each area. Baseline was defined as the last available assessment value between Week 14 and Week 20 in Phase B for this outcome measure. ANCOVA model was used for analysis.
Time frame: Baseline and Week 46
A total of 1149 participants with major depressive disorder (MDD) participated in the study from 13 July 2018 to 29 July 2022.
| Milestone | Phase A: Brexpiprazole + ADT | Phase B: Brexpiprazole + ADT | Phase C: Brexpiprazole + ADT | Phase C: Placebo + ADT |
|---|---|---|---|---|
| Started | 1149 | 0 | 0 | 0 |
| Phase a safety sample | 1136 | 0 | 0 | 0 |
| Completed | 766 | 0 | 0 | 0 |
| Not completed | 383 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 24 | 0 | 0 | 0 |
| Withdrew: Adverse event | 82 | 0 | 0 | 0 |
| Withdrew: Subject withdrew consent | 54 | 0 | 0 | 0 |
| Withdrew: Death | 1 | 0 | 0 | 0 |
| Withdrew: Non-compliance with study drug | 9 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 185 | 0 | 0 | 0 |
| Withdrew: Protocol deviation | 12 | 0 | 0 | 0 |
| Withdrew: Physician decision | 1 | 0 | 0 | 0 |
| Withdrew: Reason not specified (not due to coronavirus disease 2019 [covid-19] restriction) | 15 | 0 | 0 | 0 |
| Milestone | Phase A: Brexpiprazole + ADT | Phase B: Brexpiprazole + ADT | Phase C: Brexpiprazole + ADT | Phase C: Placebo + ADT |
|---|---|---|---|---|
| Started | 0 | 766 | 0 | 0 |
| Phase b safety sample | 0 | 765 | 0 | 0 |
| Completed | 0 | 489 | 0 | 0 |
| Not completed | 0 | 277 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 5 | 0 | 0 |
| Withdrew: Adverse event | 0 | 52 | 0 | 0 |
| Withdrew: Subject withdrew consent | 0 | 47 | 0 | 0 |
| Withdrew: Non-compliance with study drug | 0 | 9 | 0 | 0 |
| Withdrew: Lack of efficacy | 0 | 136 | 0 | 0 |
| Withdrew: Pregnancy | 0 | 1 | 0 | 0 |
| Withdrew: Protocol deviation | 0 | 9 | 0 | 0 |
| Withdrew: Physician decision | 0 | 6 | 0 | 0 |
| Withdrew: Due to covid-19 restriction | 0 | 1 | 0 | 0 |
| Withdrew: Reason not specified (not due to covid-19 restriction) | 0 | 11 | 0 | 0 |
| Milestone | Phase A: Brexpiprazole + ADT | Phase B: Brexpiprazole + ADT | Phase C: Brexpiprazole + ADT | Phase C: Placebo + ADT |
|---|---|---|---|---|
| Started | 0 | 0 | 240 | 249 |
| Phase c safety sample | 0 | 0 | 240 | 248 |
| Completed | 0 | 0 | 120 | 131 |
| Not completed | 0 | 0 | 120 | 118 |
| Withdrew: Lost to follow-up | 0 | 0 | 16 | 4 |
| Withdrew: Adverse event | 0 | 0 | 6 | 6 |
| Withdrew: Subject withdrew consent | 0 | 0 | 6 | 19 |
| Withdrew: Non-compliance with study drug | 0 | 0 | 1 | 2 |
| Withdrew: Non-compliant participants | 0 | 0 | 32 | 28 |
| Withdrew: Pregnancy | 0 | 0 | 1 | 0 |
| Withdrew: Lack of efficacy (phase c mdd relapse) | 0 | 0 | 54 | 52 |
| Withdrew: Physician decision | 0 | 0 | 0 | 1 |
| Withdrew: Reason not specified (not due to covid-19 restriction) | 0 | 0 | 4 | 6 |
Relapse criteria included:At same visit, increase in Montgomery Asberg Depression Rating Scale\[MADRS\] total score(10 items, 0=no symptoms to 6=severe symptoms,total score=0 to 60)of 50% from randomization and Clinical Global Impression-Severity of Illness \[CGI-\](8-point scale of 0=not assessed to 7=most extremely ill)score ≥4,hospitalization for depression, discontinuation for lack of efficacy/worsening of depression, active suicidality(score of ≥4 on MADRS item10 of suicidality)or yes answered on question 4 or 5 of Columbia-Suicide Severity Rating Scale\[C-SSRS\](Suicidal Ideation \[SI\] has 5 questions: wish to be dead,non-specific active suicidal thoughts,active SI with any methods \[not plan\]without intent to act,active SI with some intent to act without specific plan,active SI with specific plan,intent)or yes answered to any question in suicidal behavior section (5 questions:preparatory acts/behavior,aborted attempt,interrupted attempt,actual attempt\[non-fatal\],completed suicide).
| days | Phase C: Brexpiprazole + ADT | Phase C: Placebo + ADT |
|---|---|---|
| Phase C: Time-to-Relapse by Any Criteria as Defined in Blinded Addendum | 63.0 (8 to 185) | 63.0 (8 to 190) |
The SDS is a self-rated instrument used to measure the effect of the participant's symptoms on work/school, social life, and family/home responsibilities. For each of the three items, scores range from 0 through 10. The number most representative of how much each area was disrupted by symptoms is marked along the line from 0=not at all, to 10=extremely. The SDS total score is the mean of the 3 item responses. The SDS total score ranges from 0 to 10, with higher scores indicating greater functional impairment. Baseline was defined as the last available assessment value between Week 14 and Week 20 in Phase B for this outcome measure. Analysis of covariance (ANCOVA) model was used for analysis.
| score on a scale | Phase C: Brexpiprazole + ADT | Phase C: Placebo + ADT |
|---|---|---|
| Phase C: Change From Baseline for Randomization Phase in Sheehan Disability Scale (SDS) Mean Total Score at Week 46 | 0.72 ± 0.18 | 0.48 ± 0.18 |
Time-to-functional relapse was based on a 30% increase in the SDS mean total score from Phase C Baseline, at least one SDS sub-score at 4 or greater, and an SDS total score ≥7 when all 3 sub-scores were available. The SDS is a self-rated instrument used to measure the effect of the participant's symptoms on work/school, social life, and family/home responsibilities. For each of the three items, scores range from 0 through 10. The number most representative of how much each area was disrupted by symptoms is marked along the line from 0=not at all, to 10=extremely. Higher scores of 5 and above are associated with significant functional impairment.
| days | Phase C: Brexpiprazole + ADT | Phase C: Placebo + ADT |
|---|---|---|
| Phase C: Time-to-functional Relapse Based on SDS Criteria | 36.0 (6 to 185) | 35.0 (8 to 176) |
Relapse criteria included: At the same visit, increase in MADRS total score (10 items,7-point scale of 0=no symptoms to 6=severe symptoms, total score of 0 to 60) of 50% from randomization and CGI-S (8-point scale ranging from 0=not assessed to 7=most extremely ill) score ≥4, hospitalization for depression, discontinuation for lack of efficacy/worsening of depression, active suicidality (score of ≥4 on MADRS item 10 of suicidality) or answer of yes on question 4 or 5 of C-SSRS (SI has 5 questions: wish to be dead, non-specific active suicidal thoughts, active SI with any methods \[not plan\] without intent to act, active SI with some intent to act without specific plan, active SI with specific plan, intent) or answer of yes to any question in suicidal behavior section (5 questions: preparatory acts/behavior, aborted attempt, interrupted attempt, actual attempt \[non-fatal\], completed suicide). Percentage of participants were rounded off to single decimal point.
| percentage of participants | Phase C: Brexpiprazole + ADT | Phase C: Placebo + ADT |
|---|---|---|
| Phase C: Percentage of Participants Meeting Any Relapse Criteria | 22.5 | 20.6 |
Participants maintaining remission was defined as MADRS total score ≤10. The MADRS is a clinician-rated scale to assess depressive symptomatology during the preceding week. Participants were rated on 10 items (feelings of sadness, lassitude, pessimism, inner tension, suicidality, reduced sleep or appetite, difficulty concentrating, and a lack of interest) each on a 7-point scale from 0 (no symptoms) to 6 (symptoms of maximum severity). The total score ranges from 0 to 60 with a higher score indicating more depression.
| percentage of participants | Phase C: Brexpiprazole + ADT | Phase C: Placebo + ADT |
|---|---|---|
| Week 21 | 90.34 | 91.3 |
| Week 23 | 85.22 | 82.7 |
| Week 25 | 84.79 | 82.6 |
| Week 29 | 79.89 | 85.5 |
| Week 33 | 88.55 | 88.4 |
| Week 37 | 87.92 | 89.0 |
| Week 41 | 84.78 | 89.4 |
| Week 45 | 88.14 | 89.0 |
| Week 46 | 90.91 | 91.7 |
The MADRS is a clinician-rated scale to assess depressive symptomatology during the preceding week. Participants were rated on 10 items (feelings of sadness, lassitude, pessimism, inner tension, suicidality, reduced sleep or appetite, difficulty concentrating, and a lack of interest) each on a 7-point scale from 0 (no symptoms) to 6 (symptoms of maximum severity). The total score ranges from 0 to 60 with a higher score indicating more depression. A positive change from Baseline indicates worsening of symptoms. Baseline was defined as the last available assessment value in Phase B for this outcome measure. ANCOVA model was used for analysis.
| score on a scale | Phase C: Brexpiprazole + ADT | Phase C: Placebo + ADT |
|---|---|---|
| Phase C: Change From Baseline for Randomization Phase in MADRS Total Score at Week 46 | 4.09 ± 0.75 | 4.21 ± 0.73 |
The CGI -S was used to rate the severity of illness for each participant on an 8-point scale ranging from 0 to 7 where 0=not assessed, 1=normal, not at all ill, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severely ill, and 7=among the most extremely ill participants. A positive change from Baseline indicates worsening of illness. Baseline was defined as the last available assessment value in Phase B for this outcome measure. ANCOVA model was used for analysis.
| score on a scale | Phase C: Brexpiprazole + ADT | Phase C: Placebo + ADT |
|---|---|---|
| Phase C: Change From Baseline for Randomization Phase in CGI-S Score at Week 46 | 0.56 ± 0.10 | 0.53 ± 0.09 |
The SDS is a self-rated instrument used to measure the effect of the participant's symptoms on work/school, social life, and family/home responsibilities. For each of the three items, scores range from 0 through 10. The number most representative of how much each area was disrupted by symptoms is marked along the line from 0=not at all, to 10=extremely. Higher scores of 5 and above are associated with significant functional impairment. A positive change from Baseline indicates worsening of symptoms impacting each area. Baseline was defined as the last available assessment value between Week 14 and Week 20 in Phase B for this outcome measure. ANCOVA model was used for analysis.
| score on a scale | Phase C: Brexpiprazole + ADT | Phase C: Placebo + ADT |
|---|---|---|
| Work/School | 0.46 ± 0.22 | 0.31 ± 0.23 |
| Social Life | 0.91 ± 0.19 | 0.56 ± 0.19 |
| Family Life | 0.78 ± 0.19 | 0.52 ± 0.19 |
Collected over From first dose of study drug to 21 days after the last dose (Up to 49 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Phase A: Brexpiprazole + ADT | 1/1,149 (0.1%) | 10/1,136 (0.9%) | 398/1,136 (35%) |
| Phase B: Brexpiprazole + ADT | 0/766 (0%) | 12/765 (1.6%) | 163/765 (21.3%) |
| Phase C: Brexpiprazole + ADT | 0/240 (0%) | 1/240 (0.4%) | 25/240 (10.4%) |
| Phase C: Placebo + ADT | 0/249 (0%) | 3/248 (1.2%) | 13/248 (5.2%) |
| Event | Phase A: Brexpiprazole + ADT | Phase B: Brexpiprazole + ADT | Phase C: Brexpiprazole + ADT | Phase C: Placebo + ADT |
|---|---|---|---|---|
| Anaphylactic shockImmune system disorders | 0/1136 | 0/765 | 1/240 | 0/248 |
| CataractEye disorders | 0/1136 | 0/765 | 0/240 | 1/248 |
| Dislocation of vertebraInjury, poisoning and procedural complications | 0/1136 | 0/765 | 0/240 | 1/248 |
| EpicondylitisInjury, poisoning and procedural complications | 0/1136 | 0/765 | 0/240 | 1/248 |
| FallInjury, poisoning and procedural complications | 0/1136 | 0/765 | 0/240 | 1/248 |
| BursitisMusculoskeletal and connective tissue disorders | 0/1136 | 0/765 | 0/240 | 1/248 |
| Myocardial infarctionCardiac disorders | 0/1136 | 1/765 | 0/240 | 0/248 |
| Abdominal pain upperGastrointestinal disorders | 0/1136 | 1/765 | 0/240 | 0/248 |
| HaematemesisGastrointestinal disorders | 0/1136 | 1/765 | 0/240 | 0/248 |
| Acute hepatic failureHepatobiliary disorders | 0/1136 | 1/765 | 0/240 | 0/248 |
| Event | Phase A: Brexpiprazole + ADT | Phase B: Brexpiprazole + ADT | Phase C: Brexpiprazole + ADT | Phase C: Placebo + ADT |
|---|---|---|---|---|
| Weight increasedInvestigations | 0/1136 | 122/765 | 25/240 | 13/248 |
| HeadacheNervous system disorders | 113/1136 | 41/765 | 0/240 | 0/248 |
| AkathisiaNervous system disorders | 109/1136 | 0/765 | 0/240 | 0/248 |
| SomnolenceNervous system disorders | 90/1136 | 0/765 | 0/240 | 0/248 |
| InsomniaPsychiatric disorders | 72/1136 | 0/765 | 0/240 | 0/248 |
| NauseaGastrointestinal disorders | 64/1136 | 0/765 | 0/240 | 0/248 |
| Increased appetiteMetabolism and nutrition disorders | 60/1136 | 0/765 | 0/240 | 0/248 |
Enrolled Sample included all participants who signed the informed consent form and entered Phase A.
| Age, Continuous(years) | Phase A: Brexpiprazole + ADT |
|---|---|
| Mean | 42.3 ± 13.1 |
| Sex: Female, Male(Participants) | Phase A: Brexpiprazole + ADT |
|---|---|
| Female | 734 |
| Male | 415 |
| Ethnicity (NIH/OMB)(Participants) | Phase A: Brexpiprazole + ADT |
|---|---|
| Hispanic or Latino | 110 |
| Not Hispanic or Latino | 968 |
| Unknown or Not Reported | 71 |
| Race (NIH/OMB)(Participants) | Phase A: Brexpiprazole + ADT |
|---|---|
| American Indian or Alaska Native | 5 |
| Asian | 22 |
| Native Hawaiian or Other Pacific Islander | 5 |
| Black or African American | 159 |
| White | 868 |
| More than one race | 0 |
| Unknown or Not Reported | 90 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data will be available after marketing approval in global markets, or beginning 1-3 years following article publication. There is no end date to the availability of the data.
Access criteria: Otsuka will share data on the Vivli data sharing platform which can be found here: https://vivli.org/ourmember/Otsuka/
Data sharing details ↗ · clinical-trials.otsuka.com
Ran from Jul 2018 to primary completion in Jul 2022, 47 months.
Results were first posted in Oct 2023, 1 year 3 months after primary completion.
Of 95 industry-sponsored phase 3 interventional studies under Depressive Disorder, Major, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 33. This study's 47 months is above that.
Counting every sponsor, half of 124 studies reached it within 27 months; a quarter within 21 and three quarters within 36.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Brexpiprazole
Otsuka Pharmaceutical Development & Commercialization, Inc. →